A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to
evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell
malignancies.